HC Wainwright reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $10.00 target price on the stock.
Separately, Wedbush reiterated an outperform rating and set a $8.00 price target on shares of Compass Therapeutics in a report on Friday, March 22nd.
Read Our Latest Stock Report on CMPX
Compass Therapeutics Stock Down 1.3 %
Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). On average, equities research analysts expect that Compass Therapeutics will post -0.48 earnings per share for the current fiscal year.
Institutional Trading of Compass Therapeutics
Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its position in Compass Therapeutics by 577.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 7,855 shares of the company’s stock valued at $26,000 after purchasing an additional 6,695 shares during the last quarter. XTX Topco Ltd purchased a new stake in Compass Therapeutics in the 2nd quarter valued at $35,000. Alliancebernstein L.P. purchased a new stake in Compass Therapeutics in the 2nd quarter valued at $36,000. UBS Group AG raised its position in Compass Therapeutics by 63.5% in the 4th quarter. UBS Group AG now owns 11,819 shares of the company’s stock valued at $59,000 after purchasing an additional 4,591 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in Compass Therapeutics in the 2nd quarter valued at $38,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.
About Compass Therapeutics
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
See Also
- Five stocks we like better than Compass Therapeutics
- What is the Nikkei 225 index?
- Comprehensive Analysis of PayPal Stock
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Intuitive Surgical Stock Can Trend Much Higher This Year
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.